Form 4: Neurocrine Biosciences Executive David W. Boyer Reports Stock Transactions

David W. Boyer, Chief Corporate Affairs Officer of Neurocrine Biosciences, reports the acquisition and disposition of common stock and derivative securities, including stock options and restricted stock units, through both market sales and vesting.

Summary

• David W. Boyer, Chief Corporate Affairs Officer of Neurocrine Biosciences, filed a Form 4 detailing changes in beneficial ownership.
• The report includes transactions from February 12, 2025, and February 13, 2025.
• Boyer acquired shares through the exercise of stock options and vesting of restricted stock units (RSUs).
• He also disposed of shares through market sales, executed under Rule 10b5-1 trading plans.
• The sales were conducted at weighted average prices of $116.7939 and $116.6857 per share.
• Following the reported transactions, Boyer directly owns 3,565 shares of common stock.
• He also holds options for 34,153 shares and 4,624 restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transactions are part of a pre-arranged trading plan, so they don't necessarily reflect a change in the executive's view of the company. The vesting of RSUs is a positive, but the sales offset this.

Positives

• The vesting of RSUs and exercise of stock options indicate a potential belief in the company's future performance by the executive.

Negatives

• The sale of shares, even under a 10b5-1 plan, could be interpreted negatively by some investors, although the plan mitigates concerns about insider information.

Risks

• Continued sales by insiders, even under 10b5-1 plans, could create downward pressure on the stock price.
• Changes in company performance or market conditions could impact the value of the executive's holdings.

Future Outlook

The document outlines future vesting dates for restricted stock units, indicating continued equity-based compensation for the reporting person.

Industry Context

Insider transactions are closely watched in the biotech industry, as they can provide insights into management's view of the company's prospects. Rule 10b5-1 plans are common to avoid accusations of trading on inside information.

Comparison to Industry Standards

• Comparing Neurocrine Biosciences to companies like Biogen, Vertex Pharmaceuticals, and Amgen, insider trading activity is a common occurrence.
• The use of 10b5-1 trading plans is a standard practice among executives at these companies to manage their stock holdings and avoid potential conflicts of interest.
• The vesting schedules for RSUs are also typical, often spread out over several years to incentivize long-term performance.

Stakeholder Impact

• Shareholders may interpret the sales as a lack of confidence, although the 10b5-1 plan mitigates this concern.
• Employees may see the vesting of RSUs as a positive sign of continued investment in employee compensation.

Key Dates